Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease

Abstract excerpt

Allogeneic stem cell transplantation represents the only curative option for many patients with high risk hematological malignancies but is associated with a number of severe complications. Of these, chronic graft versus host disease (cGVHD) is the leading cause of late non-relapse mortality and of much morbidity. For over 30 years, glucocorticoids have been the mainstay of first line therapy, yet approximately...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenosine and Purinergic Signaling
• Share to Hematopoietic Stem Cell Transplantation
• Share to Mesenchymal stem cell research